Publications Update # 79 Last updated on Nov 4, 2024 Source: ReACT Group (https://www.reactgroup.org/) Previous PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (Overall Survival) Next GYOEDU Resident: Ovarian Cancer Part 3
